Background. Activating mutations in the RET-gene, which encodes a tyrosine kinase receptor, often cause medullary thyroid carcinoma (MTC). Surgical resection is the only curative treatment; no effective systemic treatment is available. We evaluated imatinib, a tyrosine kinase inhibitor currently used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumours (GIST) as a potential drug for systemic treatment of MTC, in two MTC derived cell lines expressing Multiple Endocrine Neoplasia associated mutant RET-receptors.
INTRODUCTION
Surgery is at this moment the only adequate curative intended treatment in medullary thyroid carcinoma (MTC) consisting of a total thyroidectomy with at least a central compartment dissection (1, 2) . Clearance of all neoplastic tissue in the neck may improve disease-free survival with normalization of calcitonin levels. Unfortunately, more than 50% of the patients will have persistent or recurrent disease after initial surgery and are prone to develop distant metastases for which there is no adequate systemic treatment available (3) (4) (5) (6) .The clinical presentation of MTC depends on the presence of specific mutations in the RET-gene (REarranged during Transfection), located on 10q11. The RET-gene encodes a receptor tyrosine kinase with an extracellular ligand binding domain (cysteine rich domain), a single transmembrane domain and an intracellular domain containing the catalytic tyrosine kinase domain (7) . Oncogenic activation of receptor tyrosine kinases can occur by chromosomal translocation (as found in papillary thyroid carcinomas) and by single point mutations.
Mutations in the extracellular cysteine rich domain of the RET-protein are encountered in patients having the cancer syndrome multiple endocrine neoplasia type 2A (MEN2A) and familial MTC (FMTC), while mutations in the tyrosine kinase domain are found in patients with FMTC and MEN2B (8) (9) (10) . In MEN2A, the most frequently found mutation is C634R whereas in MEN2B, the most frequently observed activating mutation in RET is M918T (10) . This mutation is also found in ~40% of sporadic MTC cases (10, 11) . These mutations and translocations lead to ligand-independent RET-autophosphorylation, resulting in a constitutively active RET-receptor. In the hereditary form of MTC, RET-mutations are always observed and RET-expression is characteristic for both the sporadic and hereditary type of MTC.
Small molecule drugs that can selectively inhibit tyrosine kinases have proven to be useful in the systemic treatment of a number of neoplastic diseases. Recently the selective tyrosine kinase inhibitor 571 (STI571, imatinib, Glivec, Gleevec, CGP57148B; Novartis Pharmaceuticals) has been developed. It belongs to the 2phenylaminopyrimidine class and it proved to target BCR-ABL, platelet derived growth factor receptor (PDGFR) (12, 13) . and c-kit receptor tyrosine kinases (14, 15) .
Currently, imatinib is clinically used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) as well as dermatofibrosarcoma protuberans (16) (17) (18) (19) (20) (21) .
Because both c-kit and RET belong to the same subfamily of tyrosine kinase receptors we investigated whether RET tyrosine kinase (RET-TK) can be inhibited by imatinib as well. Dose-dependent growth inhibition induced by imatinib in the human MTC cell line TT has been reported (22) . However, others could not reproduce these data (23) . Furthermore, it remains unclear whether the antiproliferative effect of imatinib is caused by inhibition of RET-autophosphorylation, or by induction of apoptosis, or through other mechanisms and several questions have been raised concerning the relatively high concentrations of imatinib used (23, 24) . In addition, only one MTC derived cell-line has been used in previous studies.
Aims of this study were: [1] to investigate whether imatinib can inhibit the activity of oncogenic RET mutants in vitro at clinical achievable serum levels, [2] to determine whether imatinib induces growth arrest and/or cell death in two MTC cell lines; TT a cell line reported to be derived from a sporadic MTC carrying a C634W RET mutation (25, 26) and MZ-CRC-1, a cell line derived from a malignant pleural effusion from a patient with metastatic sporadic MTC carrying a M918T mutation (26, 27) and [3] to determine whether there is specificity of imatinib for particular RET-mutations associated with MEN2A and MEN2B. The human MTC cell line MZ-CRC-1 was a gift of A. Knuth, the human MTC cell   line TT and the human hepatocellular carcinoma cell line HepG2 were obtained from   the American Type Culture Collection, Manassas VA. RPMI-1640 The PCR efficiencies for all primers used were between 96% and 99%. Data are expressed as fold induction corrected for GAPDH and HPRT. All experiments were performed in duplicate.
MATERIAL AND METHODS

Proliferation assay
To determine cell proliferation, a MTT test was employed (Roche Diagnostics, Almere, the Netherlands). Briefly, cells were seeded at a density of 1x10 5 cells/well in 96-well microtiter plates, grown overnight and exposed to different concentrations of imatinib or 0,1% DMSO as a control. After 1, 2, 3, 4 and 5 days of incubation, respectively, 10 µL of 3-(4, 5-methylthiazol-2-yl)-2, 5diphenyl-tetrazolium bromide (MTT-reagent) was added to each well and incubated at 37 °C for 4 hours. Formazan products were solubilized with 100 µL/well of the supplied detergent buffer and the plate was incubated overnight at 37 °C. The optical density was determined at 595 nm wavelength. To determine the IC 50 of imatinib (the concentration that causes 50% growth inhibition), a concentration range of imatinib was added to the wells (quadruplicates) and IC 50 was determined using linear interpolation at r = 0.5. All experiments were performed in triplicate.
Cell cycle and apoptosis analysis
For 
Statistical analysis
Values shown are depicted as mean ± standard deviation. The relationship between continuous variables was analyzed using the Student's t-test. In all tests p<0.05 was considered significant.
RESULTS
Imatinib inhibits RET-autophosphorylation in MZ-CRC-1 and TT cells in a dose-dependent manner
Lysates prepared from MZ-CRC-1 and TT cells treated with imatinib for 90 minutes were western blotted and analyzed with an anti-PY-RET (Y1062) antibody. Inhibition of RET Y1062-autophosphorylation was observed in a dose-dependent manner, with complete inhibition observed at concentrations higher than 15 µM in both cell lines ( Fig. 1 ).
To exclude that the observed reduction in RET Y1062-phosphorylation was caused by decreased RET-expression levels, the membrane was stripped and reprobed with an anti-RET primary antibody. The total amount of expressed RET did not change after exposure to imatinib for 90 minutes indicating that imatinib inhibits RETautophosphorylation but does not affect the expression level of the RET-protein ( Fig.   1 ).
Figure 1
Dose-dependent inhibition of RET-autophosphorylation in MZ-CRC-1 and TT cells after 90 minutes exposure. MZ-CRC-1 cells and TT cells were grown at a density of 5x10 5 cells/well for 48 hours and treated with different concentrations of imatinib for 90 minutes. Forty µg of total cell lysates were western blotted and blots were probed with anti-PY-RET (Y1062), stripped and probed with anti-RET.
Loading controls were done by stripping the blot again and probing for actin.
Long-term exposure to imatinib induces RET-oncoprotein degradation
In order to investigate the effects of extended exposures to imatinib on RETexpression and phosphorylation levels in MZ-CRC-1 and TT cells; cell lysates were prepared after 16 hours of exposure to imatinib and analyzed using western blotting.
Complete inhibition of RET Y1062-autophosphorylation was observed at concentrations higher than 10 µM in both cell lines (Fig. 2) . Reprobing the membrane with an anti-RET antibody showed that RET-expression levels were also reduced by long-term imatinib treatment, indicating that reduced RET Y1062-phosphorylation levels are caused by reduced RET-expression levels. In MZ-CRC-1 cells expression levels of RET-protein decreased dramatically and in TT cells RET could not be detected at concentrations of 15 and 20 µM (Fig. 2) . To determine whether equal amounts of protein were loaded, blots were stripped and reprobed with an anti-actin antibody and the total amount of actin did not change after exposure to imatinib.
Figure 2
Imatinib inhibits both autophosphorylation and expression of RET in MZ-CRC-1 and TT cells after 16
hours exposure. MZ-CRC-1 and TT cells were grown at a density of 5x10 5 cells/well for 48 hours and treated with different concentrations of imatinib for 16 hours. Forty µg of total cell lysates were western blotted and blots were probed with anti-PY-RET (Y1062), stripped and probed with anti-RET.
We used the proteasome inhibitor MG132 to determine if RET was degraded by the proteasome-ubiquitin pathway under the influence of imatinib. 10 µM MG132 was added to MZ-CRC-1 and TT cells in combination with increasing concentrations of imatinib. Cells were treated for 16 hours and whole cell lysates were western blotted and developed with an anti-RET antibody. In both cell lines, RET-expression levels were still reduced by imatinib as seen in figure 3 .
Finally, we studied the effects of imatinib on RET by means of quantitative PCR (qPCR) (Fig. 4 ). Treatment of TT cells with 15 µM imatinib for 16 hours did not result in a decreased synthesis at the transcription level. 
Imatinib inhibits proliferation of MZ-CRC-1 and TT cells
The effect of imatinib on cell growth of MTC derived cell lines was measured by means of a MTT assay. MZ-CRC-1 and TT cells were incubated with increasing concentrations of imatinib for up to five days (Fig. 5 ). Dose-dependent decrease in cell proliferation in both MZ-CRC-1 and TT cells was observed. In contrast, in HepG2 cells that do not express RET (data not shown), imatinib had no effect on the proliferation in concentrations lower than 20 µM. To determine the IC 50 of imatinib in MTC cell lines, MZ-CRC-1 and TT cells were grown in normal FCS containing medium and exposed to increasing concentrations of imatinib (Fig. 6 ). The concentrations of imatinib required inhibiting cell growth by 50% were 23 ± 2 µM for MZ-CRC-1 cells and 25 ± 4 µM for TT cells.
Imatinib promotes cell cycle arrest and apoptosis
We evaluated the contribution of cytotoxic and cytostatic components to imatinibinduced growth inhibition. First, simultaneous annexin V/ PI staining was employed to determine whether cell death occurred and to clarify the nature of cell death in the treated cultures. FACS cell cycle analysis showed that treatment with imatinib increased apoptotic cell death after 3 days of treatment (Fig. 7A ). The fraction of apoptotic cells is, however, relatively small. Second, we determined the distribution over the different cell cycle phases of MZ-CRC-1 cells treated with imatinib. For these experiments only MZ-CRC-1 cells were used as these proved to be diploid (data 
DISCUSSION
The increasing knowledge of the critical signalling pathways responsible for the growth of malignancies has lead to the development of specific inhibitors of these pathways as new tools in cancer therapy. Treatment of patients with CML, GIST and dermatofibrosarcoma protuberans with imatinib is an example of the positive clinical effects of the increasing knowledge on cancer-specific signal transduction inhibition and the use of specific signal transduction inhibitors (16) (17) (18) (19) (20) (21) .
A tumor for which no systematic treatment is yet available is MTC. MTC is a malignancy that is caused by mutations in the RET-gene, which result in a constitutive active receptor tyrosine kinase (RET-TK). Recent reports have demonstrated that inhibition of constitutive active RET-TK has cytostatic or cytotoxic effects on MTC cells (22, (29) (30) (31) (32) . As the tyrosine kinase domain of RET shows high homology with that of the tyrosine kinases which can be inhibited by imatinib, we now tested the effects of imatinib on RET.
Our analyses demonstrate that imatinib indeed has a dose-dependent inhibitory effect al. (22) . Possibly these discrepancies are caused by differences in experimental procedures employed by the different research groups. Another possibility could be that imatinib is not as effective after more than five days and that the effect is reversible.
We observed that in concentrations higher than 20 µM MZ-CRC-1 and TT cells stop proliferating. This phenomenon was also observed in cell lines that are not dependent on constitutive tyrosine kinase activity, such as HepG2 (Fig. 1 ). Probably these effects of imatinib on cell growth are due to general cytotoxicity.
Although we proved that RET is a direct target of imatinib we also have reason to believe that this inhibitor has other targets in TT and MZ-CRC-1. This was concluded since we observed clear differences in concentration necessary to inhibit RETphosphorylation compared to the concentration needed to inhibit cell proliferation.
The concentration of imatinib that is able to decrease autophosphorylation and RETcontent was above 10 and 15 µM, respectively. However, cell proliferation was already inhibited with 1 and 5 µM imatinib. This difference suggests that cell proliferation in MTC is probably not entirely dependent on RET-TK activity implying that imatinib acts on other cellular pathways as well.
When MTC cells are exposed to imatinib for a longer period, not only reduced The main mechanism of imatinib-induced growth inhibition is that of cell cycle arrest.
In cell cycle analysis we observed that imatinib induced a change in the distribution of cells over different cell cycle phases, primarily a G 0 /G 1 arrest (Fig. 6B ). Induction of apoptosis plays a (small) role as well. It should be noted that the population of MZ-CRC-1 and TT cells decreases after five days of exposure to imatinib (data not shown). It could be that non-apoptotic pathways play a role in cell death as well since after four days of treatment with imatinib only around 9% of cells were apoptotic. It should be noted that in these experiments cells have been used that grow in culture for many years. It is possible that primary MTCs respond differently to imatinib. (16) . The maximal achievable plasma levels of imatinib in patients are no higher than 6.78 µM at maximal administered doses of 600 mg daily. Higher doses of imatinib in clinical practice are difficult to achieve because of adverse effects that are hard to tolerate for the patients (42). Moreover, the lethal effects of imatinib on BCR-ABL expressing K562 cells are only observed when greater than 50% of the cellular BCR-ABL kinase activity is inhibited (13) . This suggests that a clinically relevant dose of imatinib needs to inhibit at least 50% of the target kinase activity. The IC 50 of imatinib for RET is around four times higher than the clinically relevant plasma concentrations. Therefore, the plasma concentrations that can be achieved are not likely to inhibit RET-activity enough to be beneficial in patients with MTC although MTC can behave different in an in vivo model and plasma levels of imatinib do vary to a great extent among patients.
Specific inhibition of the RET-TK is a very attractive treatment option for patients with MTC. Recently the kinase inhibitors ZD6474 (29), CEP-701 and CEP-751 (30) and PP1 (31, 32) have been shown to inhibit RET-TK at clinically achievable levels.
ZD6474, an inhibitor of the vascular endothelial growth factor (VEGF) receptor-2, has a reported IC 50 of 100 nM for RET. The indolocarbazole compounds CEP-701 and CEP-751, inhibitors of the Trk receptor tyrosine kinases, have also been shown to directly inhibit RET at nanomolar levels. PP1 shows similar IC 50 (80 nM) for RET, but inhibits other kinases at similar or lower concentrations than RET as well (32) .
None of these agents, however, have been used in large-scale placebo controlled trials in humans and side effects are not yet known. Furthermore, in MTC, prolonged administration of these inhibitors is probably necessary. It would be preferable to use a tyrosine kinase inhibitor specific for RET to minimize the potential side effects.
In conclusion, we have shown that imatinib inhibits MTC cell proliferation and RET Y1062-phosphorylation leading to decreased RET-expression in cell-lines harboring MEN2A and MEN2B associated RET-mutations. The concentration of imatinib necessary to inhibit RET in vitro makes it however yet impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC. In vivo studies will be necessary to make firm conclusions concerning the clinical application of this tyrosine kinase inhibitor as an effective treatment for MTC.
